Pearl Therapeutics (Redwood City, CA) a clinical-stage pharma company focused on metered dose inhaler products for the treatment of COPD and asthma, closed a $15M Series C financing. Participants include Clarus Ventures, New Leaf Venture Partners and 5AM Ventures.

Acton Pharmaceuticals (Marlborough, MA) a near commercial-stage pharmaceutical company focused on a HFA-propelled aerosol inhaled corticosteroid for the treatment of asthma, closed a $15M Series A financing. Participants include Sequoia Capital.

Altair Therapeutics (San Diego, CA) a clinical-stage biopharmaceutical company focused on antisense therapeutics for asthma and rhinitis, closed a $17M Series B financing. Participants include Domain Associates, AgeChem Venture Fund, Thomas McNerney & Partners and Forward Ventures.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Oxagen (United Kingdom) a clinical-stage biopharmaceutical company focused on asthma and allergic rhinitis based drug company focused on inflammation, closed a $25.M Series C financing. Participants include MPM Capital, SV Life Sciences, Advent Ventures, Bessemer Venture Partners, Omega Ventures, Abingworth, International Bio Trust, Red Abbey Venture Partners and Wellcome Trust.

Note: 2009 Year-in-Review Trend Analysis Coming [...]

Pulmatrix (Lexington, MA) a clinical-stage biotechnology company focused on the discovery and development of therapies for the treatment and prevention of infectious (COPD, asthma, and cystic fibrosis) and progressive respiratory (influenza, ventilator acquired pneumonia and respiratory syncytial virus (RSV)) diseases, closed a $30.2M Series B financing. Participants include Arch Venture Partners, Novartis Ventures Funds,Polaris Venture [...]

Aerovance (Berkeley, CA) a clinical-stage company focused on respiratory and allergic diseases, closed a $38M Series C financing. Participants include ProQuest Investments, BB Biotech Ventures, Apax Partners, Clarus Ventures, Alta Partners, Lehman Brothers, NGN Capital and Burrill & Co.

NKT Therapeutics (Newton, MA) a pre-clinical stage therapeutic company focused on asthma, closed a $8M Series A financing. Participants include SV Life Sciences and MedImmune Ventures.

Taligen Therapeutics (Aurora, CO) a development stage biotechnology company focused on the treatment of serious inflammatory diseases including asthma, macular degeneration and immune kidney disease closed a $65M Series B financing. Participants include Alta Partners, Clarus Ventures, Sanderling Ventures, Tango and High Country Venture.

Genizon Biosciences (Canada) is a therapeutic target and biomarker development stage company focused on Crohn’s disease, psoriasis, asthma and schizophrenia has closed a $31M Series D. Participants include BTF B.V.

MAP Pharmaceuticals (Mountain View, CA) a product based biopharmaceutical focused on developing novel treatments for pediatric asthma and migraine therapy closed a $50M Series D financing. The deal was led by D.E. Shaw & Co. and was joined by Perseus-Soros Biopharmaceutical Fund, Pequot Ventures, Brookside Capital Partners, Bay City Capital and Skyline Ventures.